Israel Englander Sarepta Therapeutics, Inc. Transaction History

Millennium Management LLC

$224 Billion
Q1 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 19,500 shares of SRPT stock, worth $2.53 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

19,500

Previous 116,900 83.32%

Holding current value

$2.53 Million

Previous $11.3 Million 77.61%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$93.7 - $141.53 $21.6 Million - $32.6 Million	230,009 Added 35.71%	874,147 $113 Million
Q4 2023 Feb 14, 2024	BUY	$67.31 - $124.76 $32 Million - $59.3 Million	475,231 Added 281.36%	644,138 $62.1 Million
Q2 2023 Aug 14, 2023	SELL	$106.4 - $157.19 $44.1 Million - $65.1 Million	-414,017 Reduced 71.02%	168,907 $19.3 Million
Q1 2023 May 15, 2023	BUY	$117.53 - $155.99 $21.3 Million - $28.2 Million	180,933 Added 45.01%	582,924 $80.3 Million
Q4 2022 Feb 14, 2023	SELL	$100.86 - $132.13 $31.3 Million - $41.1 Million	-310,747 Reduced 43.6%	401,991 $52.1 Million

Q3 2022 Nov 14, 2022	BUY	$75.71 - $119.24 $29.3 Million - $46.2 Million	387,072 Added 118.86%	712,738 $78.8 Million
Q2 2022 Aug 15, 2022	BUY	$62.69 - $88.44 $9.67 Million - $13.6 Million	154,251 Added 89.99%	325,666 $24.4 Million
Q1 2022 May 16, 2022	SELL	$63.15 - $90.42 $10.6 Million - $15.2 Million	-168,204 Reduced 49.53%	171,415 $13.4 Million
Q4 2021 Feb 14, 2022	BUY	$77.28 - $99.42 $17.3 Million - $22.3 Million	223,967 Added 193.66%	339,619 $30.6 Million
Q3 2021 Nov 15, 2021	BUY	$65.97 - $92.48 $3.17 Million - $4.44 Million	48,062 Added 71.11%	115,652 $10.7 Million
Q2 2021 Aug 16, 2021	SELL	$69.38 - $86.75 $21 Million - $26.2 Million	-302,593 Reduced 81.74%	67,590 $5.25 Million
Q1 2021 May 17, 2021	BUY	$72.25 - $168.95 $17.1 Million - $40 Million	236,994 Added 177.94%	370,183 $27.6 Million
Q4 2020 Feb 16, 2021	BUY	$125.56 - $178.74 $12.9 Million - $18.4 Million	102,837 Added 338.81%	133,189 $22.7 Million
Q3 2020 Nov 16, 2020	SELL	$127.12 - $172.34 $12 Million - $16.3 Million	-94,414 Reduced 75.67%	30,352 $4.26 Million
Q2 2020 Aug 14, 2020	SELL	$93.0 - $171.7 $2.32 Million - $4.29 Million	-24,978 Reduced 16.68%	124,766 $20 Million
Q1 2020 May 14, 2020	SELL	$82.38 - $131.64 $649,401 - $1.04 Million	-7,883 Reduced 5.0%	149,744 $14.6 Million
Q4 2019 Feb 14, 2020	BUY	$76.53 - $135.58 $7.39 Million - $13.1 Million	96,586 Added 158.23%	157,627 $20.3 Million
Q3 2019 Nov 14, 2019	SELL	$72.81 - $156.91 $1.42 Million - $3.06 Million	-19,504 Reduced 24.22%	61,041 $4.6 Million
Q2 2019 Aug 15, 2019	SELL	$112.21 - $151.95 $959,395 - $1.3 Million	-8,550 Reduced 9.6%	80,545 $12.2 Million
Q2 2019 Aug 14, 2019	SELL	$112.21 - $151.95 $15.3 Million - $20.8 Million	-136,659 Reduced 60.53%	89,095 $3.34 Million
Q1 2019 May 14, 2019	BUY	$106.67 - $151.68 $7.93 Million - $11.3 Million	74,349 Added 49.11%	225,754 $26.9 Million
Q4 2018 Feb 14, 2019	SELL	$97.32 - $148.76 $46.1 Million - $70.4 Million	-473,335 Reduced 75.77%	151,405 $16.5 Million
Q3 2018 Nov 14, 2018	SELL	$115.31 - $161.51 $26.9 Million - $37.7 Million	-233,667 Reduced 27.22%	624,740 $101 Million
Q2 2018 Aug 14, 2018	BUY	$71.74 - $153.69 $36.4 Million - $78 Million	507,588 Added 144.69%	858,407 $113 Million
Q1 2018 May 15, 2018	SELL	$54.02 - $82.27 $24.4 Million - $37.1 Million	-451,152 Reduced 56.26%	350,819 $26 Million
Q4 2017 Feb 14, 2018	SELL	$47.64 - $56.75 $18.1 Million - $21.6 Million	-380,297 Reduced 32.17%	801,971 $44.6 Million
Q3 2017 Nov 14, 2017	BUY	$35.73 - $47.15 $42.2 Million - $55.7 Million	1,182,268	1,182,268 $53.6 Million

Others Institutions Holding SRPT

# of Institutions

470

Shares Held

79.3M

Call Options Held

4.23M

Put Options Held

1.21M

View Full List

About Sarepta Therapeutics, Inc.

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $11.4B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

More about SRPT

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account